Are oncogenes sufficient to cause human cancer?

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 48, 2010, Pages 20599-20600

  Woodman, Scott E ^a   Mills, Gordon B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE;

CANCER GENETICS; CHROMOSOME ABERRATION; CLINICAL ARTICLE; GENE MUTATION; HUMAN; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; NOTE; ONCOGENE H RAS; PRIORITY JOURNAL; SEBORRHEIC KERATOSIS; SENESCENCE; X CHROMOSOME INACTIVATION;

CLONE CELLS; HUMANS; KERATOSIS, SEBORRHEIC; MUTATION; ONCOGENES; SIGNAL TRANSDUCTION;

EID: 78650571948     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1015563107     Document Type: Note

References (17)

1. Hafner C, et al. (2010) Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. Proc Natl Acad Sci USA 107:20780-20785.
2. Blomberg M, Jeppesen EM, Skovby F, Benfeldt E (2010) FGFR3 mutations and the skin: Report of a patient with a FGFR3 gene mutation, acanthosis nigricans, hypochondroplasia and hyperinsulinemia and review of the literature. Dermatology 220:297-305.
3. Otto W, et al. (2009) No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer. Int J Cancer 125:2205-2208.
4. Hernández S, et al. (2009) FGFR3 mutations in prostate cancer: Association with low-grade tumors. Mod Pathol 22:848-856.
5. Negrini S, Gorgoulis VG, Halazonetis TD (2010) Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11:220-228.
6. Sos ML, et al. (2009) Identifying genotype-dependent efficacy of single and combined PI3K- andMAPK-pathway inhibition in cancer. ProcNatl Acad SciUSA 106:18351-18356.
7. Collado M, Serrano M (2010) Senescence in tumours: Evidence from mice and humans. Nat Rev Cancer 10:51-57.
8. Ghosh P, Chin L (2009) Genetics and genomics of melanoma. Expert Rev Dermatol 4:131-143.
9. Dhomen N, et al. (2009) Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15:294-303.
10. Dankort D, et al. (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544-552.
11. Engelman JA (2009) Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer 9:550-562.
12. Pratilas CA, Solit DB (2010) Targeting the mitogenactivated protein kinase pathway: Physiological feedback and drug response. Clin Cancer Res 16:3329-3334.
13. Mandinova A, et al. (2009) A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. J Clin Invest 119:3127-3137.
14. Cheng L, et al. (2010) The origins of urothelial carcinoma. Expert Rev Anticancer Ther 10:865-880.
15. Wu XR (2005) Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 5:713-725.
16. Henske EP (2003) Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer 38:376-381.
17. Karbowniczek M, et al. (2010) The evolutionarily conserved TSC/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ development. J Clin Invest 120:93-102.